Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jan;61(1):46–50. doi: 10.1038/bjc.1990.10

The chemotherapeutic response of a murine (VM) model of human glioma.

R Bradford 1, J L Darling 1, D G Thomas 1
PMCID: PMC1971323  PMID: 2297489

Abstract

Using a cell line derived from the VM spontaneous murine astrocytoma, a reliable in vitro-in vivo model of human malignant glioma has been developed. In this paper we examine the effects of cytotoxic drugs with known activity against other animal brain tumour models and human disease on the in vivo VM model. The drugs BCNU, CCNU and vincristine produced significant volume reduction in tumours growing at a subcutaneous location in syngeneic animals. Procarbazine was ineffective. Similarly, BCNU, CCNU and vincristine produced small but statistically significant increases in survival of VM mice bearing the intracerebral tumour, but procarbazine was again ineffective. The modest, but significant, response of the VM model to the nitrosoureas mimics the human situation more closely than previously described animal models.

Full text

PDF
46

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradford R., Darling J. L., Thomas D. G. The development of an animal model of glioma for use in experimental neuro-oncology. Br J Neurosurg. 1989;3(2):197–210. doi: 10.3109/02688698909002795. [DOI] [PubMed] [Google Scholar]
  2. Bradley N. J., Darling J. L., Oktar N., Bloom H. J., Thomas D. G., Davies A. J. The failure of human leukocyte interferon to influence the growth of human glioma cell populations: in vitro and in vivo studies. Br J Cancer. 1983 Dec;48(6):819–825. doi: 10.1038/bjc.1983.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Geran R. I., Congleton G. F., Dudeck L. E., Abbott B. J., Gargus J. L. A mouse ependymoblastoma as an experimental model for screening potential antineoplastic drugs. Cancer Chemother Rep 2. 1974 Dec;4(4):53–87. [PubMed] [Google Scholar]
  4. Green S. B., Byar D. P., Walker M. D., Pistenmaa D. A., Alexander E., Jr, Batzdorf U., Brooks W. H., Hunt W. E., Mealey J., Jr, Odom G. L. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep. 1983 Feb;67(2):121–132. [PubMed] [Google Scholar]
  5. Koppel H., Martin J. M., Pilkington G. J., Lantos P. L. Heterogeneity of a cultured neoplastic glial line. Establishment and characterisation of six clones. J Neurol Sci. 1986 Dec;76(2-3):295–315. doi: 10.1016/0022-510x(86)90177-2. [DOI] [PubMed] [Google Scholar]
  6. Levin V. A., Freeman-Dove M. A., Maroten C. E. Dianhydrogalactitol (NSC-132313): pharmacokinetics in normal and tumor-bearing rat brain and antitumor activity against three intracerebral rodent tumors. J Natl Cancer Inst. 1976 Mar;56(3):535–539. doi: 10.1093/jnci/56.3.535. [DOI] [PubMed] [Google Scholar]
  7. Mbidde E. K., Selby P. J., Perren T. J., Dearnaley D. P., Whitton A., Ashley S., Workman P., Bloom H. J., McElwain T. J. High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer. 1988 Dec;58(6):779–782. doi: 10.1038/bjc.1988.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Pilkington G. J., Darling J. L., Lantos P. L., Thomas D. G. Cell lines (VMDk) derived from a spontaneous murine astrocytoma. Morphological and immunocytochemical characterization. J Neurol Sci. 1983 Dec;62(1-3):115–139. doi: 10.1016/0022-510x(83)90193-4. [DOI] [PubMed] [Google Scholar]
  9. Pilkington G. J., Darling J. L., Lantos P. L., Thomas D. G. Tumorigenicity of cell lines (VMDk) derived from a spontaneous murine astrocytoma. Histology, fine structure and immunocytochemistry of tumours. J Neurol Sci. 1985 Dec;71(2-3):145–164. doi: 10.1016/0022-510x(85)90056-5. [DOI] [PubMed] [Google Scholar]
  10. Rosenblum M. L., Gerosa M. A., Dougherty D. V., Wilson C. B. Improved treatment of a brain-tumor model. Part 1: Advantages of single- over multiple-dose BCNU schedules. J Neurosurg. 1983 Feb;58(2):177–182. doi: 10.3171/jns.1983.58.2.0177. [DOI] [PubMed] [Google Scholar]
  11. Sandeman D. R., Bradford R., Buxton P., Bown S. G., Thomas D. G. Selective necrosis of malignant gliomas in mice using photodynamic therapy. Br J Cancer. 1987 Jun;55(6):647–649. doi: 10.1038/bjc.1987.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Schold S. C., Jr, Rawlings C. E., 3rd, Bigner S. H., Bigner D. D. Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum. Neurosurgery. 1983 Jun;12(6):672–677. doi: 10.1227/00006123-198306000-00014. [DOI] [PubMed] [Google Scholar]
  13. Shapiro W. R., Ausman J. I., Rall D. P. Studies on the chemotherapy of experimental brain tumors: evaluation of 1,3-bis(2-chloroethyl)-l-nitrosourea, cyclophosphamide, mithramycin, and methotrexate. Cancer Res. 1970 Sep;30(9):2401–2413. [PubMed] [Google Scholar]
  14. Thompson W. R. USE OF MOVING AVERAGES AND INTERPOLATION TO ESTIMATE MEDIAN-EFFECTIVE DOSE: I. Fundamental Formulas, Estimation of Error, and Relation to Other Methods. Bacteriol Rev. 1947 Jun;11(2):115–145. [PMC free article] [PubMed] [Google Scholar]
  15. Warenius H. M., Freedman L. S., Bleehen N. M. The response of a human tumour xenograft to chemotherapy: intrinsic variation between tumours and its significance in planning experiments. Br J Cancer Suppl. 1980 Apr;4:128–132. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES